Shionogi & Co., Ltd. (SGIOF)
OTCMKTS
· Delayed Price · Currency is USD
15.00
-1.23 (-7.58%)
At close: Feb 28, 2025
Shionogi & Revenue
Shionogi & had revenue of 119.63B JPY in the quarter ending December 31, 2024, with 12.56% growth. This brings the company's revenue in the last twelve months to 456.87B, up 7.46% year-over-year. In the fiscal year ending March 31, 2024, Shionogi & had annual revenue of 435.08B with 1.97% growth.
Revenue (ttm)
456.87B JPY
Revenue Growth
+7.46%
P/S Ratio
n/a
Revenue / Employee
92.13M JPY
Employees
4,959
Market Cap
13.18B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
Mar 31, 2021 | 297.18B | -36.19B | -10.86% |
Mar 31, 2020 | 333.37B | -30.35B | -8.34% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
BioStem Technologies | 210.49M |
Shionogi & News
- 5 weeks ago - Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder - Benzinga
- 5 weeks ago - Shionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Shionogi targets JPY550B revenue through QOL focus and global expansion - Seeking Alpha
- 5 weeks ago - Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Shionogi & Co. reports 9M results - Seeking Alpha
- 4 months ago - Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content] - EURACTIV.com
- 8 months ago - Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript - Seeking Alpha